Drugs / ES102
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04991506 | Oct 2021 → May 2024 | cancer | Elpiscience Biopharma, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04730843 | Apr 2021 → Mar 2024 | cancer | Elpiscience Biopharma, Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06623136 | Apr 2025 → Feb 2027 expected | non-small cell lung carcinoma | Elpiscience (Suzhou) Biopharma, Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ES102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04991506 ↗ |
| Action | Activate | “ES102 (OX40 Agonist)” NCT04730843 ↗ |
| Route | Intravenous | “ES102 is administered via intravenous injection once every 21 days” NCT04730843 ↗ |
| Target | TNFRSF4 | “targets the human OX40 receptor (TNFRSF4)” NCT04991506 ↗ |